Abstract
ObjectiveWe evaluated the association between monocyte chemotactic protein-1 (MCP-1) and osteoarthritis.MethodsWe searched PubMed, Cochrane Library, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), VIP (Chinese database), and Wan Fang (Chinese database) (before May 10, 2020), with no language limitations. STATA version 12.0 and Revman version 5.3 were used for data analysis. The standard mean difference (SMD) and corresponding 95% confidence intervals (95% CIs) were calculated. Nine clinical studies, including 376 patients with osteoarthritis and 306 healthy controls, were evaluated.ResultsThe combined SMDs of MCP-1 expression levels suggested that MCP-1 expression was significantly higher in patients with osteoarthritis than healthy controls (SMD = 1.97, 95% CI = 0.66–3.28, p = 0.003). Moreover, subgroup analysis implied that osteoarthritis patients from both Asians and mixed populations had higher MCP-1 expression levels than controls, whereas Caucasians did not (p > 0.05). Serum MCP-1 levels (SMD = 2.83, 95% CI = 1.07–4.6, p < 0.00001) were significantly higher in patients with osteoarthritis than in controls; however, this difference was not significant in synovial fluid and cartilage tissue. Subgroup analysis for ethnicity showed that MCP-1 levels were significantly higher in Chinese, Dutch, and Brazilian patients with osteoarthritis than in control groups, although significant differences were not observed for American and Italian subgroups.ConclusionsOur meta-analysis demonstrated that MCP-1 expression levels were higher in patients with osteoarthritis than in healthy controls and that MCP-1 may play important roles in the progression of osteoarthritis. Serum MCP-1 levels may serve as a potential biomarker for the diagnosis of osteoarthritis.
Highlights
Osteoarthritis (OA) is a type of degenerative articular cartilage disease related to inflammation and is characterized by joint stiffness and pain
Selection criteria The study selection criteria were as follows: (1) only case-control or cross-sectional studies in the population to explore the relationship between monocyte chemotactic protein-1 (MCP-1) and OA were included, (2) patients in the studies must have met the diagnostic criteria for OA, (3) studies provided means and standard deviations or means and standard errors of MCP-1 levels in patients with OA and healthy controls, and (4) studies must have had sufficient and original data
The results showed that MCP-1 levels were significantly higher in patients with OA than in controls (SMD = 1.97, 95% Confidence interval (CI) = 0.66–3.28, p = 0.003; Fig. 3)
Summary
Osteoarthritis (OA) is a type of degenerative articular cartilage disease related to inflammation and is characterized by joint stiffness and pain. In OA, cytokine and chemokine production, the synovium response, cell infiltration, and inflammatory pathway activation affect disease progression and have been observed in animal models. Chemokines are inducible secreted proinflammatory cytokines with a relative molecular mass of approximately 8–10 kDa. The main function of chemokines is to stimulate different types of cells, including neutrophils, monocytes, lymphocytes, and fibroblasts, to undergo chemotaxis, thereby mediating cell aggregation and activation at the site of inflammation and facilitating tissue damage and repair. The main function of chemokines is to stimulate different types of cells, including neutrophils, monocytes, lymphocytes, and fibroblasts, to undergo chemotaxis, thereby mediating cell aggregation and activation at the site of inflammation and facilitating tissue damage and repair These molecules play important roles in various biological processes, such as immune surveillance, organ development, angiogenesis, and immune responses [5–7]. Many experimental studies have demonstrated that chemokines are involved in the pathogenesis of OA and may be new targets for the early intervention and treatment of OA [8–12]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
